SCHEMBL3231981

SCHEMBL3231981

CN1CCN(c2ccc(F)c(F)c2)c2ccc(N3CCn4c(nnc4C(F)(F)F)C3)cc2C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 15/20 0.38
DPP8 Q6V1X1 7/20 0.38
DPP7 Q9UHL4 3/20 0.38
SCN9A Q15858 1/20 0.37
AMY1A P0DUB6 1/20 0.34
PTPN1 P18031 1/20 0.34
FAP Q12884 2/20 0.34
DPP9 Q86TI2 3/20 0.34
ACE P12821 1/20 0.34
HTR2A P28223 1/20 0.34
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
RECQL P46063 1/20 0.33
PTK2B Q14289 1/20 0.33
ALDH1A1 P00352 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP8B1 Q9UNU6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3232100 0.90 SCN9A (0.40) DPP4DPP8DPP7SCN9ADPP9
SCHEMBL3231360 0.90 SCN9A (0.38) DPP4DPP8DPP7SCN9ADPP9
SCHEMBL3237513 0.90 SCN9A (0.40) DPP4DPP8SCN9ADPP9CYP8B1
SCHEMBL3225628 0.89 SCN9A (0.42) DPP4DPP8SCN9AKDM4EGAA
SCHEMBL3220899 0.89 MAOB (0.40) DPP4DPP8DPP7SCN9ADPP9
SCHEMBL3229007 0.88 SCN9A (0.37) DPP4DPP8DPP7SCN9AKDM4E
SCHEMBL3240198 0.88 DPP4 (0.39) DPP4DPP8SCN9ADPP9HTR2A
SCHEMBL3228425 0.87 HTR3A (0.45) SCN9AHTR2A
SCHEMBL3479739 0.81 GAA (0.46) SCN9AKDM4EGAAMAPTMAPK1
SCHEMBL3479762 0.76 SCN9A (0.49) SCN9AHTR2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D DPP4 1454/4885DPP8 2406/4885DPP7 2812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.